Universidad Nacional de Colombia
unal.edu.coLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
38
Active
6
Phase 3
11
Total enrollment
8,018,271
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| LC16m8 | — | — | — | — | — | 1 | |
| Peptide (neoantigen) pulsed autologous Dendritic cell | — | — | — | — | — | 1 |
Next readouts
- 2024-08-20
- 2027-06-01
Top conditions
- COVID2
- Breast Cancer Female2
- Arrhythmias1
- Dry Eye1
- Sjogren Syndrome1
- Arthritis, Rheumatoid1
- CPR1
- Cardiac Arrest (CA)1
Frequently asked questions about Universidad Nacional de Colombia
- How many clinical trials does Universidad Nacional de Colombia have on ClinicalTrials.gov?
- Universidad Nacional de Colombia is listed as the lead sponsor on 38 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universidad Nacional de Colombia's trials are in Phase 3?
- 11 of Universidad Nacional de Colombia's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Universidad Nacional de Colombia focus on?
- Universidad Nacional de Colombia's most-studied conditions on ClinicalTrials.gov are COVID, Breast Cancer Female, Arrhythmias, Dry Eye, Sjogren Syndrome.
- When are Universidad Nacional de Colombia's next clinical trial readouts?
- Universidad Nacional de Colombia has 2 upcoming primary-completion readouts tracked here; the soonest is “Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia”, expected around 2024-08-20.